Exchange Traded Concepts LLC Buys 431 Shares of Agilent Technologies, Inc. $A

Exchange Traded Concepts LLC grew its stake in Agilent Technologies, Inc. (NYSE:A) by 3.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 11,372 shares of the medical research company’s stock after acquiring an additional 431 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Agilent Technologies were worth $1,342,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of A. Vanguard Group Inc. increased its stake in Agilent Technologies by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 33,408,626 shares of the medical research company’s stock worth $3,908,141,000 after purchasing an additional 240,965 shares in the last quarter. Pictet Asset Management Holding SA boosted its position in Agilent Technologies by 2.5% during the 1st quarter. Pictet Asset Management Holding SA now owns 5,341,870 shares of the medical research company’s stock worth $624,888,000 after acquiring an additional 128,131 shares during the last quarter. Generation Investment Management LLP lifted its position in shares of Agilent Technologies by 19.8% in the first quarter. Generation Investment Management LLP now owns 4,983,556 shares of the medical research company’s stock worth $582,976,000 after purchasing an additional 824,243 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Agilent Technologies by 18.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,836,105 shares of the medical research company’s stock worth $448,748,000 after purchasing an additional 604,124 shares in the last quarter. Finally, Impax Asset Management Group plc lifted its position in shares of Agilent Technologies by 3.6% in the first quarter. Impax Asset Management Group plc now owns 2,931,794 shares of the medical research company’s stock worth $342,961,000 after purchasing an additional 102,365 shares in the last quarter.

Agilent Technologies Trading Up 0.0%

Shares of Agilent Technologies stock opened at $126.36 on Tuesday. The business has a fifty day simple moving average of $120.37 and a two-hundred day simple moving average of $115.81. Agilent Technologies, Inc. has a 1 year low of $96.43 and a 1 year high of $153.84. The company has a market capitalization of $35.82 billion, a price-to-earnings ratio of 29.66, a P/E/G ratio of 3.93 and a beta of 1.24. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.71.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.37. The business had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The company’s quarterly revenue was up 10.1% on a year-over-year basis. During the same quarter last year, the firm posted $1.32 EPS. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Research analysts forecast that Agilent Technologies, Inc. will post 5.58 EPS for the current year.

Agilent Technologies Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 22nd. Shareholders of record on Tuesday, September 30th will be given a dividend of $0.248 per share. The ex-dividend date is Tuesday, September 30th. This represents a $0.99 annualized dividend and a yield of 0.8%. Agilent Technologies’s dividend payout ratio (DPR) is presently 23.24%.

Insiders Place Their Bets

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,508 shares of the stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total transaction of $177,099.52. Following the transaction, the chief executive officer owned 37,448 shares in the company, valued at $4,397,893.12. This trade represents a 3.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Wall Street Analyst Weigh In

A number of analysts have recently commented on A shares. Wells Fargo & Company boosted their price objective on shares of Agilent Technologies from $140.00 to $150.00 and gave the stock an “overweight” rating in a research report on Monday, September 15th. TD Cowen increased their price objective on Agilent Technologies to $150.00 and gave the company a “buy” rating in a report on Thursday, May 29th. JPMorgan Chase & Co. cut their price objective on Agilent Technologies from $160.00 to $155.00 and set an “overweight” rating for the company in a report on Thursday, May 29th. Wall Street Zen downgraded Agilent Technologies from a “buy” rating to a “hold” rating in a report on Friday, September 5th. Finally, Evercore ISI cut their price objective on Agilent Technologies from $130.00 to $128.00 and set an “in-line” rating for the company in a report on Thursday, August 28th. Six investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $140.08.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.